SREBF2 and atherosclerosis: Metformin’s CV beneficial effects of atherosclerosis prevention are mediated in part through its ability of inhibiting the oxidative stress-mediated accumulation of cholesterol via AMPK-SREBP2 (sterol regulatory element-binding protein 2)-LDLR (low-density lipoprotein receptor) axis in vascular cells [63].